Cell Therapeutics News

All signs point to emerging biotech company Rainbow Coral Corp. finding its feet in biotechnology at exactly the right time: The biotech industry is off to a great start in the early stages of 2012.

Biotechnology companies are often a point of high risk and high reward for many traders since many of these companies success can greatly change depending on the news surrounding a single drug.

GTXI Sudden Surge, What's Up? CTIC in Free Fall. ECIT Stalls. AMLN Trending Up. STEV Levels Off.

JERICHO, NY, January 30, 2012, Lone Star Gold, Inc. announced today that their information in now available through S&P Capital IQ's Market Access Program.

Shares of the following companies are having unusual moves in U.S. trading. Stock symbols are in parentheses, and prices are as of 10:20 a.m. in New York.

Very early on Monday morning, Cell Therapeutics, Inc. told Wall Street that they need additional time to prepare for the highly anticipated review of the Pixuvri NDA by the FDA's Oncologic Drugs Advisory Committee at its February 9, 2012 meeting.

Cell Therapeutics Inc said on Monday it has voluntarily withdrawn the marketing application for its cancer drug, sending its shares down 17 percent before the bell.

Cutting-edge stem cell research is producing new breakthroughs that could potentially revolutionize the treatment of currently incurable diseases from cancer to brain injuries to headaches.

Shares of the following companies are having unusual moves in U.S. trading. Stock symbols are in parentheses, and prices are as of 9:40 a.m. in New York.

Despite closing 2 percent lower, shares of Home Depot Inc. are climbing .20 percent in late market trading.A The company announced it has acquired Redbeacon.com, an online home-services website that pairs homeowners with contractors.A Shares of Lowe's Companies Inc.

Cell Therapeutics, Inc. Expects That the European Medicines Agency's Committee for Medicinal Products for Human Use May Issue an Opinion on the Marketing Authorization Application SEATTLE, Jan.

Cell Therapeutics, Inc. Expects That the European Medicines Agency's Committee for Medicinal Products for Human Use May Issue an Opinion on the Marketing Authorization Application on Pixuvria in Mid-February A /PRNewswire/ -- Cell Therapeutics, Inc.